Alzheimer's Drug Development by Eli Lilly

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

There seems to be a bit of confusion about the various drug trials currently underway by Eli Lilly. Here is a brief summary of their activity:

The IDENTITY trials are enrolling patients aged 55+ in over 30 countries including the USA. The compound in these studies is a gamma-secretase inhibitor that is hypothesized to reduce the accumulation of amyloid plaques in the brain.

The more recently announced EXPEDITION trials are enrolling patients aged 55+ in 16 countries including the USA. These studies are measuring the potential effects of an anti-amyloid monoclonal antibody (Solanezumab) delivered via intravenous infusion.

More details about each trial including how to inquire about enrolling can be found in this announcement from Eli Lilly.